Endocrine Abstracts

Introduction: Nivolumab, an anti–programmed cell death-1 (PD-1) monoclonal antibody, is a promising treatment of variety advanced malignancies. Immune checkpoint inhibitors can cause immune-related adverse events, including endocrine pathology. Destructive thyroiditis is one of the most frequently observed nivolumab-induced endocrine irAEs which associated with the presence of anti–thyroid peroxidase antibodies (TPO-Abs) and anti-thyroglobulin antibodies (Tg-Abs) pri...